These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
    Author: Owusu C, Lash TL, Silliman RA.
    Journal: Breast J; 2007; 13(4):374-82. PubMed ID: 17593042.
    Abstract:
    To investigate the effectiveness of adjuvant tamoxifen in older women with early-stage breast cancer. Between 1997 and 1999, women > or = 65 years old at diagnosis with stage I-IIIa breast cancer were recruited from four geographic regions of the United States and followed prospectively for 5 years after diagnosis. Data sources included tumor registries, medical records review, and telephone interviews. The primary end points were breast cancer-specific and overall survival ascertained by matching identifying data with the National Death Index and Social Security Administration master death file. Tamoxifen prescription was operationalized as tamoxifen prescribed by 6 months after diagnosis. Survival analysis was undertaken using Kaplan-Meier curves and Cox proportional hazards modeling. We studied 689 women whose average age was 74.2 years at diagnosis (SD = 6.3, range 65-96 years). The median follow-up was 67 months (range 3.5-88 months). Of the 689 patients, 519 (76%) were prescribed tamoxifen. The 5-year breast cancer-specific survival was 93% (95% CI = 90-95) and 89% (95% CI = 83-94) for the ever tamoxifen and never tamoxifen groups, respectively. The ratio of adjusted breast cancer mortality hazards was 0.61 (95% CI = 0.31-1.12) for the ever tamoxifen group versus the never tamoxifen group. Similarly, the 5-year overall survival was 81% (95% CI = 76-85) and 70% (95% CI = 61-78) for the ever tamoxifen and never tamoxifen groups, respectively, with an adjusted hazard ratio of 0.53 (95% CI = 0.37-0.77). Adjuvant tamoxifen is associated with improvement in 5-year breast cancer-specific and overall survival in older women with early-stage breast cancer.
    [Abstract] [Full Text] [Related] [New Search]